Floatz logo

Budesonide

Melanoma

Bristol-Myers SquibbSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

435 Active assets in the Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Cyclophosphamide
Primmune Therapeutics, Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

Budesonide is also rated in:

asthmaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
B
Indicative · Phase 4
63 / 100
View asset →
primary biliary cholangitisDormant
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →